Guardant Health (GH) Chief People Officer reports insider stock sales

Q: Who reported an insider transaction at Guardant Health (GH)?

The filing reports transactions by Terilyn J. Monroe , who serves as Chief People Officer of Guardant Health, Inc.

Q: What type of transaction did the Guardant Health (GH) insider execute?

Terilyn J. Monroe reported open-market sales (code S) of Guardant Health common stock , as shown in the non-derivative securities table.

Q: How many Guardant Health shares did Terilyn J. Monroe sell on January 21, 2026?

On January 21, 2026, she sold 1,703 , 3,619 , and 3,249 shares of Guardant Health common stock in three separate reported sale entries.

Q: How many Guardant Health shares does Terilyn J. Monroe own after the reported sales?

Following the reported transactions, Terilyn J. Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.

Q: Did the Form 4 report any derivative securities for Guardant Health (GH)?

The filing’s derivative securities table shows no reported transactions in options, warrants, or other derivative securities for this reporting date.

Q: How were the sale prices for the Guardant Health insider transactions determined?

Each reported price is a weighted average sales price , and the filing notes the shares were sold in multiple transactions within stated price ranges, with detailed trade data available upon request.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Guardant Health Chief People Officer Terilyn J. Monroe reported multiple open-market sales of company stock. On January 21, 2026, she sold 1,703 shares of Guardant Health common stock at a weighted average price of $112.3418 per share, 3,619 shares at a weighted average price of $113.4793 per share, and 3,249 shares at a weighted average price of $115.6978 per share. Each sale was executed in multiple transactions within disclosed price ranges. After these sales, Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.

Insider Trade Summary

Net Seller: 8,571 shares ($977,902)

Net Sell 3 txns

Insider Monroe Terilyn J.

Role Chief People Officer

Sold 8,571 shs ($978K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,703	$112.3418	$191K
Sale	Common Stock	3,619	$113.4793	$411K
Sale	Common Stock	3,249	$115.6978	$376K

Holdings After Transaction: Common Stock — 27,858 shares (Direct)

Footnotes (1)

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.77. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.015 to $114.010. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.345 to $116.150. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

01/22/2026 - 05:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monroe Terilyn J.

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/21/2026		S		1,703	D	$112.3418⁽¹⁾	27,858	D
Common Stock	01/21/2026		S		3,619	D	$113.4793⁽²⁾	24,239	D
Common Stock	01/21/2026		S		3,249	D	$115.6978⁽³⁾	20,990	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.77. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.015 to $114.010. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.345 to $116.150. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who reported an insider transaction at Guardant Health (GH)?

The filing reports transactions by Terilyn J. Monroe, who serves as Chief People Officer of Guardant Health, Inc.

What type of transaction did the Guardant Health (GH) insider execute?

Terilyn J. Monroe reported open-market sales (code S) of Guardant Health common stock, as shown in the non-derivative securities table.

How many Guardant Health shares did Terilyn J. Monroe sell on January 21, 2026?

On January 21, 2026, she sold 1,703, 3,619, and 3,249 shares of Guardant Health common stock in three separate reported sale entries.

At what prices were the Guardant Health (GH) shares sold by the Chief People Officer?

The reported weighted average sale prices were $112.3418, $113.4793, and $115.6978 per share, each based on multiple trades within specified price ranges.

How many Guardant Health shares does Terilyn J. Monroe own after the reported sales?

Following the reported transactions, Terilyn J. Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.

Did the Form 4 report any derivative securities for Guardant Health (GH)?

The filing’s derivative securities table shows no reported transactions in options, warrants, or other derivative securities for this reporting date.

How were the sale prices for the Guardant Health insider transactions determined?

Each reported price is a weighted average sales price, and the filing notes the shares were sold in multiple transactions within stated price ranges, with detailed trade data available upon request.